Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on January 24, 2024. The report addresses a regulatory notice received from The Nasdaq Capital Market regarding the listing status of the Company's common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance issue rather than financial performance results.
Material Changes and Listing Status
On January 24, 2024, the Company received a Notification Letter from Nasdaq stating non-compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Rule. The Company's common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the stock.
Outlook, Management Commentary, and Risks
- Compliance Period: The Company has an initial 180-calendar day period, until July 22, 2024, to regain compliance.
- Compliance Criteria: To achieve compliance, the bid price must close at $1.00 per share or more for a minimum of 10 consecutive business days before the deadline.
- Management Action: The Company intends to actively monitor the closing bid price and evaluate available options to regain compliance.
- Risks: Failure to regain compliance within the specified timeframe could result in delisting from The Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current closing bid price of PHIO common stock to assess proximity to the $1.00 threshold.
- Monitor the stock's performance over the next 10 consecutive business days to determine if compliance is achieved early.
- Review subsequent filings for any announcements regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Confirm the exact date of the 180-day compliance deadline (July 22, 2024) and any potential extensions.